Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options [PDF]
MedicinaVulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery.
Ramunė Narutytė +2 more
doaj +2 more sources
Fractional CO2 Laser for Treatment of Vulvovaginal Atrophy: A Short Time Follow-up [PDF]
Journal of Family and Reproductive Health, 2020 Objective: The aim of this study was to evaluate the safety and efficacy of fractional CO2 laser for treatment of vulvovaginal atrophy. Materials and methods: In this clinical trial study, we evaluated the laser effect on vulvovaginal atrophy in 47 women
Zinat Ghanbari +6 more
doaj +2 more sources
Comment on Jankovic et al. Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy. Medicina 2024, 60, 1059 [PDF]
MedicinaWe write with concerns regarding the recent publication of “Understanding the Benefits of CO2 Laser Treatment for Vulvovaginal Atrophy” [...]
Catherine Broomfield +2 more
doaj +2 more sources
Topical Spermidine Hyaluronate (Spd-HA) in Vulvovaginal Atrophy: A Preliminary Study [PDF]
MedicinaBackground and Objectives: Genitourinary syndrome of menopause (GSM), previously termed vulvovaginal atrophy (VVA), is a prevalent hypoestrogenic condition characterized by genital, sexual, and urinary symptoms. Although hormonal therapies are effective,
Irene Porcari +9 more
doaj +2 more sources
Comparison of the Effects of Vaginal Royal Jelly and Vaginal Estrogen on Quality of Life, Sexual and Urinary Function in Postmenopausal Women [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Several causes can disturb the quality of life in postmenopausal women. Stress, urinary incontinence is one of the factors that can influence the quality of life of women, since they evade social activities and limit their behavior ...
Fatemeh Seyyedi +2 more
doaj +4 more sources
Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study. [PDF]
PLoS One, 2022 This prospective, open-label, multicentre, multinational, randomised trial investigated the non-inferiority of treatment with a vaginal hormone-free moisturising cream compared to a vaginal estriol (0.1%) cream in a panel of post-menopausal women ...
Garcia de Arriba S +5 more
europepmc +3 more sources
Medical and Health Science Journal, 2020 Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue.
Zettira Maulida Prasha, Hari Paraton
doaj +3 more sources
Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy [PDF]
International Journal of Women's Health, 2013 Sharon J Parish,1 Rossella E Nappi,2 Michael L Krychman,3 Susan Kellogg-Spadt,4 James A Simon,5 Jeffrey A Goldstein,6 Sheryl A Kingsberg7 1Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Obstetrics and Gynecology, IRCCS Policlinico ...
Parish SJ +6 more
doaj +3 more sources
Climacteric, 2018 Objectives: The primary objective of the European Vulvovaginal Epidemiological Survey (EVES) was to assess, at a country level, the prevalence of postmenopausal women with vulvovaginal atrophy (VVA) confirmed by gynecological clinical assessment among all postmenopausal women attending menopause centers.
Santiago Palacios +4 more
openalex +5 more sources
Vulvovaginal atrophy: modern approaches to diagnostics and management
Zaporožskij Medicinskij ŽurnalThe aim of the review is to analyze the latest data on the current state of diagnosis and management of a common benign vulvar and vaginal disease in postmenopausal women – atrophic vulvovaginitis.
V. H. Siusiuka +4 more
doaj +4 more sources